Literature DB >> 7977648

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

J Reifenberger1, G Reifenberger, L Liu, C D James, W Wechsler, V P Collins.   

Abstract

The molecular genetic alterations of oligodendroglial tumors and mixed gliomas of the central nervous system were studied in a series of 37 cases (8 oligodendrogliomas, 13 anaplastic oligodendrogliomas, 8 oligoastrocytomas, and 8 anaplastic oligoastrocytomas). A total of 180 polymorphic loci and 5 nonpolymorphic gene loci, distributed over all chromosomes, were examined by restriction fragment length polymorphism analysis. Loss of heterozygosity was most frequently observed for loci on 19q with a commonly deleted region at 19q13.2-q13.4 distal to the CYP2a gene and proximal to the D19S22 locus. The incidence of allelic loss on 19q was particularly high (81%) in oligodendroglial tumors and equal to 31% in mixed gliomas. More than 75% of the tumors with allelic deletions on 19q also showed loss of heterozygosity for loci on 1p with one tumor showing only loss of alleles distal to the NGFB gene (1p13-pter). Seven (19%) tumors had lost alleles from 17p with the deleted region including the TP53 tumor suppressor gene in all cases. Sequencing of the TP53 transcripts from exons 2 to 10, however, did not reveal mutations of the remaining allele in any of these tumors. Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas demonstrated an increased incidence of additional allelic losses involving most frequently chromosomes 9p and 10. Gene amplification was detected in two anaplastic tumors, affecting the epidermal growth factor receptor gene in both cases, with additional amplification of the renin gene at 1q32 in one of these cases. In total our results indicate both differences and similarities between the molecular genetic alterations in tumors with oligodendroglial and astrocytic differentiation. The loss of genetic information from 19q and 1p as well as the rarity of TP53 mutations in oligodendroglial tumors suggests that the early events in their oncogenesis are distinct from those associated with astrocytic tumors. However, similarities are indicated by the allelic losses on 9p and 10 in the anaplastic tumors, suggesting the utilization of common pathways of progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977648      PMCID: PMC1887413     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Clonal genomic alterations in glioma malignancy stages.

Authors:  C D James; E Carlbom; J P Dumanski; M Hansen; M Nordenskjold; V P Collins; W K Cavenee
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

2.  Specific chromosomal abnormalities in malignant human gliomas.

Authors:  S H Bigner; J Mark; P C Burger; M S Mahaley; D E Bullard; L H Muhlbaier; D D Bigner
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

3.  Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression.

Authors:  N C Dracopoli; P Harnett; S J Bale; B Z Stanger; M A Tucker; D E Housman; R F Kefford
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Mitotic recombination of chromosome 17 in astrocytomas.

Authors:  C D James; E Carlbom; M Nordenskjold; V P Collins; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Oligodendroglioma: incidence and biological behavior in a defined population.

Authors:  S J Mørk; K F Lindegaard; T B Halvorsen; E H Lehmann; T Solgaard; R Hatlevoll; S Harvei; J Ganz
Journal:  J Neurosurg       Date:  1985-12       Impact factor: 5.115

6.  Chromosomal composition of a series of 22 human low-grade gliomas.

Authors:  J A Rey; M J Bello; J M de Campos; M E Kusak; S Moreno
Journal:  Cancer Genet Cytogenet       Date:  1987-12

7.  Deletion mapping in human renal cell carcinoma.

Authors:  U Bergerheim; M Nordenskjöld; V P Collins
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

8.  Structural chromosomal abnormalities in human medulloblastoma.

Authors:  S H Bigner; J Mark; H S Friedman; J A Biegel; D D Bigner
Journal:  Cancer Genet Cytogenet       Date:  1988-01

9.  Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984).

Authors:  T S Nijjar; W J Simpson; T Gadalla; M McCartney
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

10.  Factors possibly influencing the prognosis of oligodendroglioma.

Authors:  Z M Sun; S Genka; N Shitara; A Akanuma; K Takakura
Journal:  Neurosurgery       Date:  1988-05       Impact factor: 4.654

View more
  141 in total

1.  Alleletyping of an oligodendrocyte-type-2 astrocyte lineage derive from a human glioblastoma multiforme.

Authors:  X Mao; R Barfoot; R A Hamoudi; M Noble
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 2.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

4.  Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics.

Authors:  Mahfoud Assem; Zita Sibenaller; Supreet Agarwal; Maha S Al-Keilani; Mohammad A Y Alqudah; Timothy C Ryken
Journal:  OMICS       Date:  2012-03

Review 5.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

6.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

7.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

Review 8.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors:  Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

10.  Tumor prognostic factors and the challenge of developing predictive factors.

Authors:  Emma B Holliday; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.